Neurology · Tacoma, WA
NPI
1447258496
Since 2005
Specialty
Neurology
Code 173F00000X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
915 6th Ave, Suite 200
Tacoma, WA, 98405
Phone (253) 403-7299
Groups this clinician bills Medicare through
Medicare paid, 2024
$61K
1,193 services
Medicare patients, 2024
732
Average age 73
Drug cost, 2024
$623K
2,786 prescriptions
Company payments, 2025
$69.91
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kimberly A Mebust was code 95800 (sleep study), 254 times for 249 patients. In total Kimberly A Mebust billed 1,193 services in 24 codes, and Medicare paid $61K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-03-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95800 Sleep Study | Facility | 254 | 249 | $25.81 | $6,556 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 186 | 168 | $12.94 | $2,408 |
| 99213 Office E&M - Established | Office | 162 | 147 | $64.92 | $11K |
| 99214 Office E&M - Established | Office | 134 | 107 | $81.49 | $11K |
| 95810 Sleep Study | Facility | 90 | 90 | $82.44 | $7,420 |
| 95811 Sleep Study | Facility | 78 | 75 | $85.68 | $6,683 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 58 | 54 | $12.89 | $747 |
| 99213 Office E&M - Established | Facility | 53 | 47 | $49.80 | $2,639 |
| 99214 Office E&M - Established | Facility | 42 | 36 | $67.83 | $2,849 |
| 99204 Office E&M - New | Office | 25 | 25 | $97.64 | $2,441 |
| 99203 Office E&M - New | Office | 25 | 25 | $78.62 | $1,965 |
| 99215 Office E&M - Established | Office | 15 | 14 | $121.04 | $1,816 |
| 95806 Sleep Study | Facility | 11 | 11 | $28.36 | $312 |
By year: 2022 $66K for 943 services; 2023 $61K for 897 services; 2024 $61K for 1,193 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kimberly A Mebust prescribed most often to Medicare patients was Pramipexole Dihydrochloride (Pramipexole Di-Hcl), with 212 prescriptions and refills. In total Kimberly A Mebust wrote 2,786 Medicare prescriptions that cost $623K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 212 | 437 | 62 | $3,517 |
| Pregabalin Generic | 211 | 278 | 39 | $3,670 |
| Gabapentin Generic | 208 | 375 | 58 | $3,747 |
| Zolpidem Tartrate Generic | 182 | 231 | 41 | $1,224 |
| Trazodone Hcl Generic | 168 | 279 | 45 | $1,431 |
| Clonazepam Generic | 164 | 198 | 30 | $1,265 |
| Armodafinil Generic | 94 | 136 | 21 | $10K |
| Eszopiclone Generic | 86 | 104 | 16 | $1,384 |
| Tizanidine Hcl Generic | 81 | 107 | 17 | $1,146 |
| Doxepin Hcl Generic | 79 | 103 | 18 | $2,006 |
| Temazepam Generic | 68 | 68 | 13 | $346 |
| Modafinil Generic | 66 | 82 | 16 | $2,861 |
| Neupro Rotigotine | 52 | 54 | Under 11 | $46K |
| Ropinirole Hcl Generic | 50 | 104 | 14 | $1,417 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 48 | 87 | 12 | $417 |
Brand drugs: 290 claims; generic drugs: 2,496 claims; opioid claims: 77.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kimberly A Mebust $69.91 ($69.91 in general payments such as food, travel and fees) from 1 company. The largest payer was Inspire Medical Systems, Inc. with $69.91.
| Company | Payments | Amount |
|---|---|---|
| Inspire Medical Systems, Inc. INSP | 1 | $69.91 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.